September 10, 2025CancersOpen Access

Inflammation-Based Prognostication in Advanced-Stage NSCLC: A Retrospective Cohort Study

View Full Paper

Ask AI

Bookmark

High baseline NLR significantly increased the risk of progression in advanced-stage NSCLC patients.
Median progression-free survival was 8.2 months, and median overall survival was 14.5 months in the cohort studied.
An increase in NLR at 12 months further elevated the risk of disease progression, warranting its consideration for prognosis.
Low hemoglobin showed a non-significant association with progression risk, indicating its secondary role compared to NLR.

Discussion

No takes yet. Share an insight, caveat, or question.

Retrospective cohort analysis reveals NLR's impact on progression-free survival in NSCLC, suggesting its use as a prognostic indicator.

Golban et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark